A Phase 1 trial of Anixa Biosciences’ (NASDAQ:ANIX) breast cancer vaccine and women survivors were featured in an article on the website of England’s Daily Mail newspaper.
Anixa’s CEO, Amit Kumar, Ph.D., described the vaccine’s novel mechanism of action, adding that if the immune system is properly trained by vaccination, “then when those [breast] cancer cells arise, the immune system will destroy them and they will never have a chance to multiply into a tumor.”
The article can be accessed here.
